Inotiv

Cox1 knockout rats

HsdSage:SD-Cox1em1Sage

Order Today
+1 800 793 7287
Description
Pricing
Technical resources
Cryopreserved

Typically heterozygous rats are cryo-recovered in 10-12 weeks to an age of 7 weeks old. Subsequently homozygous rats to an age of 7 weeks old can be produced within 20-22 weeks.

  • Homozygous knockout rats exhibit complete loss of COX1 protein via Western blot
  • Background Strain: Sprague-Dawley

Availability: Cryopreserved as heterozygous embryos
Zygosity: Heterozygous

Cyclooxygenase (COX), also known as prostaglandin synthase (PHS) and prostaglandin endoperoxide synthetase (PES), is an enzyme that is responsible for formation of important biological mediators called prostanoids, including prostaglandins, prostacyclin and thromboxane. Rats deficient in COX1 can be used for studying inflammation, thrombosis, vascular defects, platelet defects and alterations in platelet aggregation.


Origin:

The Cox1 Knockout Rat model was originally created at SAGE Labs, Inc. in St. Louis, MO and distributed out of the Boyertown, PA facility. The line continues to be maintained through the original SAGE Labs animal inventory acquired by Envigo, then Envigo was acquired by Inotiv in 2021.

Available regions:

For pricing information, please contact us using the phone number above.

Research use and related publications
  • Asthma
  • Colitis
  • Crohn's disease
  • Immunology
  • Multiple sclerosis
  • Platelet defects/Platelet aggregation
  • Renal dysplasia
  • Rheumatoid arthritis
  • Inflammation/Autoimmune disorders
  • Thrombosis/Cardiac fibrosis
  • Vascular defects

2025 Product guide

Receive a copy of our current research models and services product guide.

Download today  
SCIENCE Surgeon - clinical

SCIENTIFIC

INSIGHTS

Keep up-to-date with the latest industry thinking and scientific insights

Explore today
90-anni-globe-widget

More than 90 years of working together, to build a healthier and safer world

Explore our history
Decoration

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
Subscribe now